UNIVERSITI PUTRA MALAYSIA

MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITORS OF METALLOPROTEINASE -1 AND -2 AS POTENTIAL NOVEL BIOMARKERS IN GESTATIONAL HYPERTENSION

JABRULLAH AB. HAMID

FPSK(m) 2010 17
MATRIX METALLOPROTEINASE -9 AND TISSUE INHIBITORS OF METALLOPROTEINASE -1 AND -2 AS POTENTIAL NOVEL BIOMARKERS IN GESTATIONAL HYPERTENSION

JABRULLAH AB. HAMID

MASTER OF SCIENCE
UNIVERSITI PUTRA MALAYSIA

2010
MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITORS OF METALLOPROTEINASE -1 AND -2 AS POTENTIAL NOVEL BIOMARKERS IN GESTATIONAL HYPERTENSION

By

JABRULLAH AB. HAMID

Thesis Submitted to the School of Graduates Studies, Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Master of Science

November 2010
Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirements for the degree of Master of Science

MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITORS OF METALLOPROTEINASE-1 AND -2 AS POTENTIAL NOVEL BIOMARKERS IN GESTATIONAL HYPERTENSION

By

JABRULLAH AB HAMID

November 2010

Chairman: Norhafizah Mohtarrudin, MBBS, M (Path)

Faculty: Faculty of Medicine and Health Sciences

Gestational hypertension (GH) is a common disorder during pregnancy, which could progress to preeclampsia (PE) and even causing various subsequent maternal and perinatal complications. A cluster of enzymes called matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinase (TIMP) are thought to be involved in the pathophysiology of the disease. The purpose of this study was to determine the circulating (serum) levels of the MMP-9, TIMP-1 and TIMP-2 in GH patients and compare with normotensive pregnant women as well as to correlate the pregnancy outcomes, such as preterm delivery, poor progress, foetal distress, mode of delivery, low birth weight, small for gestational age, low apgar score, meconium-stained liquor and neonatal intensive care unit admission. A total of 118 patients were randomly selected in this unmatched case-control study. Subjects include GH women (n=54) and controls (n=64) were healthy normotensive pregnant women, selected from those who have attended the outpatient clinics at General Hospital Kuala Lumpur and
Serdang Hospital during May 2008 to January 2009 and fulfilled the specified selection criteria. All the patients were followed up until delivery, all desired patients’ information and the outcomes of the pregnancies were gathered from medical records. The levels of each biomarker were measured by using specific Enzyme-Link Immunosorbent Assay (ELISA) technique and the MMP/TIMPs ratios were calculated manually. MMP-9 was found slightly higher in the GH group ($p=0.085$). In the subgroup analysis based on parity, MMP-9 and MMP-9/TIMP-1 ratio were slightly higher in nulliparous GH group ($p=0.064$ and $p=0.079$ respectively), and TIMP-1 was slight higher in multiparous GH group ($p=0.062$). However all these findings do not reach statistical significance at $p=0.05$. A weak positive correlation (statistically significant) was found between maternal age and TIMP-1 in GH group ($r=0.278$, $p=0.047$). Similarly, a weak positive correlation (statistically significant) was found between gestational age and TIMP-2 in control group ($r=0.318$, $p=0.010$). There is no correlation found between MMP and TIMPs with blood pressure levels. Pre-eclampsia developed in 8 (15%) GH women. The rate of low birth weight ($p=0.040$), small for gestational age / intra-uterine growth restriction ($p=0.018$), meconium-stained liquor ($p=0.018$) and Neonatal Intensive Care Unit admission ($p=0.001$) were significantly increased in GH group. Although the rate of poor progress, caesarean sections, instrumental deliveries, low APGAR score and neonatal jaundice were increased in GH, they were not statistically significant ($p>0.05$). Preterm delivery rate was not significantly different between GH and normotensive pregnancy. Even though lacking in statistical significance, a higher level of MMP-9 was found in the GH group. Similarly comparisons made
based on parity were noted to be lower, approaching statistical significance, especially in the nulliparous subgroup. This could also be a sign of the increased risk of PE and GH in nulliparous pregnancy. The different patterns of MMP-9 and TIMP-1 and -2 alterations between nulliparous and multiparous women could also suggest different underlying pathophysiological changes between the two subgroups. The analysis comparing pregnancy outcomes between the two groups showed increased risk for various adverse outcomes as well as maternal and perinatal complications among GH women.
Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

MATRIX METALLOPROTEINASE-9 DAN TISU PENGHALANG METALLOPROTEINASE-1 DAN -2 SEBAGAI BIOMARKER YANG BERPOTENSI SEMASA HIPERTENSI GESTASI

Oleh

JABRULLAH AB HAMID

November 2010

Pengerusi: Norhafizah Mohtarrudin, MBBS, M (Path)

Fakulti: Fakulti Perubatan dan Sains Kesihatan

Penyakit hipertensi gestasi (GH) adalah suatu penyakit yang biasa di kalangan wanita mengandung, yang mana ianya boleh menyebabkan pre-eklampsia (PE) dan juga pelbagai komplikasi kepada ibu dan anak yang akan dilahirkan. Satu kluster enzim dipanggil Matrix Metalloproteinase (MMP) dan Tisu Penghalang Metalloproteinase (TIMP) dikatakan terlibat di dalam proses pato-fisiologi penyakit terlibat. Kajian ini adalah untuk mengkaji paras kandungan MMP-9, TIMP-1 and TIMP-2 di dalam serum, dikalangan pesakit GH untuk perbandingan dengan wanita mengandung yang sihat serta untuk mengaitkannya dengan hasil (outcome) kehamilan seperti tidak cukup bulan (preterm), tidak cukup perkembangan (poor progress), distres janin (foetal distress), kaedah kelahiran (mode of delivery), rendah berat lahir (low birth weight), kecil untuk umur gestasi (small for gestational age), rendah skor apgar (low apgar score), lumuran cecair mekonium (meconium-stained liquor), penyakit kuning neonatal (neonatal jaundice) dan kemasukan ke unit rawatan rapi neonatal
(admission to NICU). Sebanyak 118 pesakit dipilih secara rawak di dalam kajian kes-kawalan (tanpa perjodohan) ini. Kes adalah wanita GH (n=54); dan kawalan adalah wanita hamil yang sihat (n=64), dipilih melalui kedatangan ke klinik pesakit luar di 2 hospital (Hospital Besar Kuala Lumpur dan Hospital Serdang) semasa Mei 2008 hingga Januari 2009 dan memenuhi kriteria pemilihan. Semua perkembangan pesakit akan diikuti hingga proses kelahiran, dan semua maklumat yang dikehendaki didapati melalui rekod perubatan. Paras kandungan setiap penanda-bio (biomarker) disukat dengan menggunakan teknik Enzyme-Link Immunosorbent Assay (ELISA) yang spesifik, dan nisbah MMP/TIMP kemudiannya dihitung secara manual. MMP-9 didapati lebih tinggi sedikit di dalam kumpulan GH (p=0.085). Di dalam analisis sub-kumpulan atas dasar pariti, MMP-9 dan nisbah MMP-9/TIMP-1 didapati lebih tinggi sedikit di dalam kumpulan nuliparus GH (p=0.064 dan p=0.079 masing-masing), dan TIMP-1 lebih tinggi sedikit di dalam kumpulan multiparus GH (p=0.062). Positif korelasi yang lemah didapati di antara umur maternal dengan TIMP-1 di dalam kumpulan GH (r=0.278, p=0.047). Positif korelasi yang lemah juga didapati di antara umur gestasi dengan TIMP-2 di dalam kumpulan kawalan (r=0.318, p=0.010). Tiada korelasi didapati di antara MMP dan semua TIMP dengan paras tekanan darah. PE terjadi di dalam 8 (15%) pesakit GH. Kadar rendah berat kelahiran (p=0.040), kecil untuk umur gestasi / perkembangan intra-uterine terbatas (intra-uterine growth restriction) (p=0.018), lumuran ceair mekonium (p=0.018) dan kemasukan ke Unit Rawatan Rapi Neonatal (NICU) (p=0.001) meningkat secara signifikan di dalam kumpulan GH. Kadar tidak cukup perkembangan (poor progress), pembedahan kelahiran caesarean (caesarean section), kelahiran dengan bantuan instrumen,
rendah nilai APGAR dan sakit kuning neonatal didapati meningkat di dalam GH tetapi tidak mencapai statistik signifikan ($p>0.05$). Kadarr kelahiran awal penggal didapati tidak berbeza di antara kumpulan GH dan kawalan. Walaupun kekurangan nilai signifikan secara statistiknya, paras MMP-9 yang lebih tinggi didapati di kalangan kumpulan GH. Analisis mencatatkan nilai $p$ yang lebih rendah, menghampiri nilai statistik signifikan, terutamanya di dalam sub-kumpulan nuliparus.

Ini boleh menjadi petanda kepada peningkatan risiko menghidapi PE dan GH di kalangan kehamilan nuliparus. Corak perubahan MMP dan TIMP yang berbeza di antara wanita nuliparus dan multiparus juga boleh bermaksud kepada perubatan patofisiologi yang berbeza di antara kedua-dua sub-kumpulan. Analisis perbandingan mengenai hasil kehamilan di antara kedua-dua kumpulan menunjukkan peningkatan risiko serta beberapa komplikasi kepada ibu dan anak di kalangan wanita GH.
ACKNOWLEDGEMENTS

First, I wish to show my appreciation and gratitude to my project supervisor, Dr. Norhafizah Mohtarrudin, for giving me opportunity to experiencing the research and work under her guidance, encouragement, advice, and suggesting throughout this successful study. A special note of appreciation also goes to my supervisory committee member, Dr. Malina Osman for helpful advice and statistical guidance, and Dr. Andi Anggeriana Andi Asri for practical support and constructive suggestion.

I am sincerely grateful to the financial support by UPM under the Research University Grant Scheme – RUGS (04/01/07/0101RU). I would also like to express my most gratitude for tremendous help and contribution of personnel from Hospital Besar Kuala Lumpur (staff nurses of O&G Department and Medical Record Unit K3 Wisma Kayu) and Hospital Serdang (O&G Department) during the samples and data collection period. I would like to thank Dr. Rohani Aziz for the assistance and guidance during the initiation of the project at Hospital Kajang. My acknowledgement also comprehensive to all member in Laboratory of Chemical Pathology (UPM), and all individuals from Faculty of Medicine and Health Sciences whose involved in this project.

Lastly, I would also like to express my sincere gratitude to my parents and family members for their endless moral support, dedication and encouragement. With all contribution from those aforementioned, this study can be as successfully accomplished. Alhamdulillah.
I certify that a Thesis Examination Committee has met on 12 November 2010 to conduct the final examination of Jabrullah bin Ab. Hamid on his thesis entitled “Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinases-1 and -2 as Potential Novel Biomarkers in Gestational Hypertension” in accordance with the Universities and Universiti College Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Master of Science.

Members of the Examination Committee are as follows:

**Shiran Mohd Sidik, PhD**
Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

**Sabariah Abdul Rahman, PhD**
Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

**Chong Pei Pei, PhD**
Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

**Siti Aishah Md. Ali, PhD**
Lecturer
Faculty of Medicine
Universiti Kebangsaan Malaysia Medical Centre (UKMMC)
(External Examiner)


BUJANG KIM HUAT, PhD
Professor and Deputy Dean,
School of Graduates Studies,
Universiti Putra Malaysia.
This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirements for the Degree of Master of Science. The members of the Supervisory committee were as follows:

**Norhafizah Mohtarrudin, MBBS, M (Path)**  
Medical Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Malina Osman, MD, M. Comm. Health**  
Medical Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

**Andi Anggeriana Andi Asri, MD, MRCOG, MOG**  
Medical Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

__________________________  
HASANAH MOHD GHAZALI, PhD  
Professor and Dean,  
School of Graduates Studies,  
Universiti Putra Malaysia.

Date:
DECLARATION

I declare that the thesis is my original work except for the quotations and citations which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other local institutions.

________________________
JABRULLAH AB. HAMID

Date: 12 November 2010
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>ii</td>
</tr>
<tr>
<td>ABSTRAK</td>
<td>v</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>viii</td>
</tr>
<tr>
<td>Approval</td>
<td>ix</td>
</tr>
<tr>
<td>Declaration</td>
<td>x</td>
</tr>
<tr>
<td>List of Tables</td>
<td>xi</td>
</tr>
<tr>
<td>List of Figures</td>
<td>xv</td>
</tr>
<tr>
<td>Glossary of Terms</td>
<td>xvi</td>
</tr>
<tr>
<td>Glossary of Terms</td>
<td>xvii</td>
</tr>
</tbody>
</table>

## CHAPTER

1. **INTRODUCTION**
   - 1.1 Research background
     - 1.1.1 Gestational hypertension (GH) 1
     - 1.1.2 Biomarkers in medical diagnosis 2
     - 1.1.3 Problem statement 3
   - 1.2 Objectives
     - 1.2.1 General objective 5
     - 1.2.2 Specific objectives 5
   - 1.3 Hypothesis 6
   - 1.4 Significance of the study 7

2. **LITERATURE REVIEW**
   - 2.1 Hypertension (HTN)
     - 2.1.1 Definition and classification 8
     - 2.1.2 Types and causes of HTN 9
     - 2.1.3 Risk factors of HTN 10
   - 2.2 Pregnancy
     - 2.2.1 Physiological adaptation in pregnancy 13
     - 2.2.2 Complications in pregnancy 15
   - 2.3 Hypertensive Disorder of Pregnancy (HDP)
     - 2.3.1 Incidence 16
     - 2.3.2 Classification and definition 17
     - 2.3.3 Aetiology and risk factors 20
     - 2.3.4 Pathophysiology 24
     - 2.3.5 Management and therapy 32
   - 2.4 Biomarkers in pregnancy
     - 2.4.1 Biomarkers 38
     - 2.4.2 Current biomarkers under consideration 40
   - 2.5 Matrix Metalloproteinase (MMP) system
     - 2.5.1 Matrix Metalloproteinases (MMPs) 43
     - 2.5.2 Inhibition of MMPs activity 47
     - 2.5.3 Biological features of MMPs and Tissue Inhibitors of MMPs (TIMPs) 49
3 METHODOLOGY

3.1 Study location and duration

3.2 Study design

3.3 Sampling

3.3.1 Study population

3.3.2 Sampling population

3.3.3 Sampling frame

3.3.4 Sampling method

3.3.5 Sample size

3.3.6 Sampling unit

3.4 Instrument and data collection

3.4.1 Instruments

3.4.2 Data collection technique

3.4.3 Quality control

3.5 Data processing and statistical analysis

3.6 Study ethics

3.7 Definition of terms and variables

3.7.1 Independent variables

3.7.2 Dependent variables

3.8 Operational definition

4 RESULTS

4.1 Descriptive analysis of socio-demographic distribution and related clinical information in study population

4.1.1 Background of respondents

4.1.2 Socio-demographic characteristics

4.1.3 Clinical information

4.2 Determination and comparative measurements of MMP and TIMPs in GH and normotensive pregnancy

4.2.1 Levels of MMP and TIMPs in GH and control group

4.2.2 Levels of MMP and TIMPs in GH and control group according to parity

4.3 Determination of MMP and TIMPs in relation to maternal age and gestational age

4.3.1 Association between MMP and TIMPs with maternal age

4.3.2 Association between MMP and TIMPs with gestational age

4.4 Association between MMP and TIMPs with the blood pressure level

4.5 Determination of obstetric outcomes in GH and normotensive pregnancies
4.5.1 Pregnancy outcomes 89
4.5.2 Foetal outcomes 90
4.6 Association between MMP and TIMPs with maternal complications and foetal outcomes in GH and normotensive pregnancies 91

5 DISCUSSION 94
5.1 Socio-demographic distribution and related clinical information in the study population 94
5.1.1 Socio-demographic characteristic 94
5.1.2 Clinical information 95
5.2 Comparative measurement of MMP and TIMPs in GH and normotensive pregnant women 97
5.2.1 The levels of MMP and TIMPs in GH and normotensive group 97
5.2.2 The effects of parity on MMP and TIMPs levels 101
5.2.3 Associated issues regarding the MMP and TIMPs 103
5.3 Determination of MMP and TIMPs in relation to maternal and gestational age 104
5.3.1 Association between MMP and TIMPs with maternal age 104
5.3.2 Association between MMP and TIMPs with gestational age 106
5.4 Association between MMP and TIMPs with the blood pressure level 108
5.5 Pregnancy outcomes in GH and normotensive women 110
5.5.1 Antepartum and intrapartum complications 110
5.5.2 Mode of delivery 112
5.5.3 Foetal complications 113
5.6 Association between MMP and TIMPs with maternal complications and foetal outcomes in GH and normotensive pregnancy 114

6 SUMMARY, CONCLUSION, AND RECOMMENDATIONS FOR FUTURE RESEARCH 116
6.1 Research summary and conclusions 116
6.2 Limitations of study 119
6.3 Future direction 120

REFERENCES 122
APPENDICES 150
BIODATA OF STUDENT 158
LIST OF PUBLICATIONS 159